查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070507

膠質母細胞瘤藥物市場規模、佔有率、成長、全球產業分析、區域洞察及2026-2034年預測。

Glioblastoma Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

膠質母細胞瘤藥物市場的成長要素

全球膠質母細胞瘤藥物市場預計在2025年達到7.9億美元，2026年成長至8.3億美元，並在2034年達到12.1億美元，預測期內複合年成長率（CAGR）為4.82%。這一市場成長的主要促進因素包括膠質母細胞瘤發病率的上升、抗癌藥物研發投入的增加、聯合治療的日益普及以及免疫療法研發管線的擴展。儘管膠質母細胞瘤是一種高度侵襲性疾病，長期治療成功率有限，但製藥公司仍在持續加強對創新療法的投入，以期提高患者的存活率。

到 2025 年，北美將引領全球膠質母細胞瘤藥物市場，佔市場總收入的 37.97%，這得益於其先進的神經腫瘤學基礎設施、強大的臨床試驗生態系統和較高的治療採納率。

市場規模及預測

  • 2025年市場規模：7.9億美元
  • 2026年市場規模：8.3億美元
  • 2034年市場規模：12.1億美元
  • 複合年成長率（2026-2034年）：4.82%

腦腫瘤負擔日益加重，加上標靶治療和免疫療法研究的進步，預計將在整個預測期內創造持續的成長機會。

主要市場趨勢

人們對基於免疫療法的治療方法越來越感興趣。

影響膠質母細胞瘤藥物市場的最重要趨勢之一是免疫療法的快速發展。儘管手術、放射線治療和化療等傳統療法在臨床實踐中仍然佔主導地位，但它們的療效有限，尤其是在復發病例中。

因此，製藥公司正在增加以下方面的投資：

  • 癌症疫苗
  • 細胞免疫療法
  • 免疫查核點抑制劑
  • 個人化腫瘤特異性療法

例如，2025 年 12 月，Imvax 宣布其針對新診斷的膠質母細胞瘤患者開發的 IGV-001（一種患者特異性全癌細胞免疫療法）的 2b 期臨床試驗取得了積極結果。

市場促進因素

對有效治療的巨大未滿足需求

膠質母細胞瘤仍然是最具侵襲性和最難治療的腦瘤之一。現有治療方法對提高存活率的幫助有限，而且復發率仍然極高。

在對更有效療法的需求不斷成長的推動下，各公司正在加快臨床開發步伐並尋求監管部門的支持。 2025年10月，Myosin Therapeutics公司的MT-125獲得了美國FDA的簡審類，顯示監管機構對創新型膠質母細胞瘤療法的支持力度正在加強。

市場限制因素

快速產生抗藥性和疾病復發

市場成長的主要障礙之一是治療抗藥性的快速發展。大多數患者即使接受了手術、放射治療和化療，仍會復發。

對Temozolomide等標準療法的抗藥性會降低長期治療效果，並給尋求在臨床試驗中證明生存期大幅延長的研發公司帶來重大挑戰。

市場機遇

拓展臨床研發管線

市場正經歷臨床開發平臺活躍度的提升，從而創造了長期成長機會。許多針對新型生物通路的臨床實驗藥物正進入臨床研發階段。

2025年8月，Lantan Pharma旗下子公司Starlight Therapeutics獲得FDA批准，啟動針對膠質母細胞瘤的Ib/IIa期臨床試驗。這體現了製藥業為滿足未被滿足的醫療需求而持續做出的努力。

市場挑戰

腫瘤異質性

膠質母細胞瘤不僅在不同患者之間，在同一腫瘤內部也表現出顯著的生物學變異性。這種異質性使得治療方案的研發變得複雜，單一療法不太可能對廣泛的患者群體有效。

因此，製藥公司在設計複雜的臨床試驗、增加研發風險以及確定可能從治療中受益的患者群體方面面臨挑戰。

區域分析

北美洲

  • 2025年市場規模：3億美元
  • 2025年最大的區域市場

該地區充分利用其在先進的醫療基礎設施、活躍的腫瘤學研究以及廣泛參與臨床試驗方面的優勢。

歐洲

  • 2026年市場規模：2.3億美元

歐洲憑藉其健全的公共醫療體系和不斷增加的先進癌症治療機會，持續擴大其市場。

亞太地區

  • 2026年市場規模：1.9億美元

癌症治療基礎設施的改善和癌症研究投入的增加正在推動這一成長。

主要國家展望（2026 年）

  • 美國：2.9億美元
  • 中國：8000萬美元
  • 德國：5000萬美元
  • 英國：5000萬美元
  • 日本：4000萬美元
  • 印度：2000萬美元

近期產業趨勢包括啟動多項臨床試驗、獲得 FDA 認證、新型免疫療法進展以及旨在改善治療效果的基因組檢測合作研究。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 按主要疾病和主要國家分類的癌症盛行率
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品發布等）
  • 主要國家和地區的監管狀況

第5章：2021-2034年全球膠質母細胞瘤藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物分類
    • Temozolomide
    • Bevacizumab
    • Carmustine
    • Lomustine
    • 丙卡巴肼
    • Irinotecan
    • 其他
  • 市場分析、洞察與預測：按藥物類別分類
    • 烷化劑
    • VEGF/血管生成抑制劑
    • 亞硝基脲
    • 鉑化合物
    • 拓樸異構酶抑制劑
    • 免疫查核點抑制劑
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 非專利的
  • 市場分析、洞察與預測：按療法分類。
    • 標靶治療
    • 免疫療法
    • 化療
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美膠質母細胞瘤藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲膠質母細胞瘤藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區膠質母細胞瘤藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲膠質母細胞瘤藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲膠質母細胞瘤藥物市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Merck & Co., Inc.
    • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Accord Healthcare
    • Camber Pharmaceuticals, Inc.
    • Fresenius Kabi AG
    • Zydus Lifesciences Ltd.
    • Amneal Pharmaceuticals, Inc.
Product Code: FBI116045

Growth Factors of glioblastoma drugs Market

The global glioblastoma drugs market was valued at USD 0.79 billion in 2025 and is projected to grow from USD 0.83 billion in 2026 to USD 1.21 billion by 2034, registering a CAGR of 4.82% during the forecast period. The market growth is primarily driven by the increasing prevalence of glioblastoma, growing investments in oncology drug development, rising adoption of combination therapies, and the expansion of immunotherapy-based treatment pipelines. Despite the aggressive nature of glioblastoma and limited long-term treatment success, pharmaceutical companies continue to invest heavily in innovative therapies aimed at improving patient survival outcomes.

North America dominated the global glioblastoma drugs market in 2025, accounting for 37.97% of the total market revenue due to its advanced neuro-oncology infrastructure, strong clinical trial ecosystem, and high treatment adoption rates.

Market Size and Forecast

  • 2025 Market Size: USD 0.79 Billion
  • 2026 Market Size: USD 0.83 Billion
  • 2034 Market Size: USD 1.21 Billion
  • CAGR (2026-2034): 4.82%

The growing burden of brain tumors and increasing research into targeted therapies and immune-based treatments are expected to create sustainable growth opportunities across the forecast period.

Key Market Trends

Rising Focus on Immunotherapy-Based Treatments

One of the most significant trends shaping the glioblastoma drugs market is the increasing development of immunotherapy-based therapies. Traditional treatments such as surgery, radiation, and chemotherapy continue to dominate clinical practice, but their effectiveness remains limited, especially in recurrent disease.

As a result, pharmaceutical companies are increasingly investing in:

  • Cancer vaccines
  • Cell-based immunotherapies
  • Immune checkpoint inhibitors
  • Personalized tumor-specific therapies

For example, in December 2025, Imvax announced positive Phase 2b trial results for IGV-001, a patient-specific whole-tumor-cell immunotherapy developed for newly diagnosed glioblastoma patients.

Market Drivers

High Unmet Need for Effective Therapies

Glioblastoma remains one of the most aggressive and difficult-to-treat brain cancers. Existing therapies offer limited survival benefits and recurrence rates remain extremely high.

Growing demand for more effective treatments is encouraging companies to accelerate clinical development activities and seek regulatory support. In October 2025, Myosin Therapeutics received U.S. FDA Fast Track designation for MT-125, highlighting increasing regulatory encouragement for innovative glioblastoma therapies.

Market Restraints

Rapid Treatment Resistance and Disease Recurrence

One of the major barriers to market growth is the rapid development of treatment resistance. Most patients experience disease recurrence even after undergoing surgery, radiation, and chemotherapy.

Resistance to standard therapies such as temozolomide reduces long-term treatment effectiveness and creates significant challenges for developers attempting to demonstrate meaningful survival benefits in clinical trials.

Market Opportunities

Expanding Clinical Pipeline

The market is witnessing substantial pipeline activity, creating long-term growth opportunities. Numerous investigational therapies targeting novel biological pathways are entering clinical development.

In August 2025, Lantern Pharma's subsidiary Starlight Therapeutics received FDA clearance to initiate a Phase Ib/2a clinical study for glioblastoma, reflecting the industry's continued commitment to addressing unmet treatment needs.

Market Challenges

Tumor Heterogeneity

Glioblastoma exhibits significant biological variability among patients and even within individual tumors. This heterogeneity complicates treatment development and reduces the likelihood of a single therapy being effective across the broader patient population.

As a result, drug developers face complex clinical trial designs, increased development risks, and challenges in identifying responsive patient groups.

Segment Analysis

By Drug

The Temozolomide segment dominated the market in 2025 due to its established role as the standard first-line chemotherapy for glioblastoma treatment.

The Others segment is expected to register the fastest growth with a CAGR of 8.50% during the forecast period.

By Drug Class

Alkylating Agents held the largest market share owing to widespread use of temozolomide-based treatment regimens.

The Immune Checkpoint Inhibitors segment is projected to grow at a CAGR of 11.92% through 2034.

By Age Group

The Adult segment dominated the market due to the significantly higher incidence of glioblastoma among adults.

The Pediatric segment is expected to grow at a CAGR of 7.61%.

By Type

The Generic Drugs segment accounted for the largest share due to broad availability and lower treatment costs.

By Therapy

Chemotherapy remained the leading therapy segment in 2025, supported by continued reliance on temozolomide-based treatment protocols.

The Immunotherapy segment is expected to witness the fastest growth at a CAGR of 12.72%.

By Route of Administration

The Oral segment dominated the market because temozolomide is primarily administered orally, improving patient convenience and treatment adherence.

By Distribution Channel

Hospital Pharmacies accounted for the largest market share owing to the specialized nature of glioblastoma treatment and hospital-centered care pathways.

Regional Analysis

North America

  • 2025 Market Value: USD 0.30 Billion
  • Largest regional market in 2025

The region benefits from advanced healthcare infrastructure, strong oncology research activities, and extensive clinical trial participation.

Europe

  • 2026 Market Value: USD 0.23 Billion

Europe continues to expand due to strong public healthcare systems and increasing access to advanced cancer therapies.

Asia Pacific

  • 2026 Market Value: USD 0.19 Billion

Growth is supported by improving cancer treatment infrastructure and increasing investments in oncology research.

Key Country Insights (2026)

  • U.S.: USD 0.29 Billion
  • China: USD 0.08 Billion
  • Germany: USD 0.05 Billion
  • U.K.: USD 0.05 Billion
  • Japan: USD 0.04 Billion
  • India: USD 0.02 Billion

Competitive Landscape

The market remains highly consolidated with major players focusing on product launches, clinical trials, partnerships, and pipeline expansion.

Key companies include:

  • Merck & Co., Inc.
  • Genentech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Accord Healthcare
  • Camber Pharmaceuticals, Inc.
  • Fresenius Kabi AG
  • Zydus Lifesciences Ltd.

Recent industry developments include multiple clinical trial initiations, FDA designations, novel immunotherapy advancements, and genomic testing collaborations aimed at improving treatment outcomes.

Conclusion

The global glioblastoma drugs market is expected to experience steady growth from USD 0.79 billion in 2025 to USD 1.21 billion by 2034. Rising incidence of brain tumors, increasing investment in immunotherapy and targeted therapies, and a robust clinical pipeline are driving market expansion. While challenges such as tumor heterogeneity, treatment resistance, and high recurrence rates remain significant, continued innovation and regulatory support are expected to improve therapeutic options and create new growth opportunities throughout the forecast period.

Segmentation By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Region

By Drug * Temozolomide

  • Bevacizumab
  • Carmustine
  • Lomustine
  • Procarbazine
  • Irinotecan
  • Others

By Drug Class * Alkylating agents

  • VEGF / angiogenesis inhibitors
  • Nitrosoureas
  • Platinum compounds
  • Topoisomerase inhibitors
  • Immune checkpoint inhibitors
  • Others

By Age Group * Pediatric

  • Adults

By Type * Branded

  • Generic

By Therapy * Targeted Therapy

  • Immunotherapy
  • Chemotherapy
  • Others

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital pharmacies

  • Drug stores & retail pharmacies
  • Online pharmacies

By Region * North America (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, By Key Indication, By Key Countries /Regions
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Temozolomide
    • 5.1.2. Bevacizumab
    • 5.1.3. Carmustine
    • 5.1.4. Lomustine
    • 5.1.5. Procarbazine
    • 5.1.6. Irinotecan
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Alkylating Agents
    • 5.2.2. VEGF/Angiogenesis Inhibitors
    • 5.2.3. Nitrosoureas
    • 5.2.4. Platinum Compounds
    • 5.2.5. Topoisomerase Inhibitors
    • 5.2.6. Immune Checkpoint Inhibitors
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generic
  • 5.5. Market Analysis, Insights and Forecast - By Therapy
    • 5.5.1. Targeted therapy
    • 5.5.2. Immunotherapy
    • 5.5.3. Chemotherapy
    • 5.5.4. Others
  • 5.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.6.1. Oral
    • 5.6.2. Parenteral
  • 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.7.1. Hospital Pharmacies
    • 5.7.2. Drug Stores & Retail Pharmacies
    • 5.7.3. Online Pharmacies
  • 5.8. Market Analysis, Insights and Forecast - Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. Asia Pacific
    • 5.8.4. Latin America
    • 5.8.5. Middle East & Africa

6. North America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Temozolomide
    • 6.1.2. Bevacizumab
    • 6.1.3. Carmustine
    • 6.1.4. Lomustine
    • 6.1.5. Procarbazine
    • 6.1.6. Irinotecan
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Alkylating Agents
    • 6.2.2. VEGF/Angiogenesis Inhibitors
    • 6.2.3. Nitrosoureas
    • 6.2.4. Platinum Compounds
    • 6.2.5. Topoisomerase Inhibitors
    • 6.2.6. Immune Checkpoint Inhibitors
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generic
  • 6.5. Market Analysis, Insights and Forecast - By Therapy
    • 6.5.1. Targeted therapy
    • 6.5.2. Immunotherapy
    • 6.5.3. Chemotherapy
    • 6.5.4. Others
  • 6.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.6.1. Oral
    • 6.6.2. Parenteral
  • 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.7.1. Hospital Pharmacies
    • 6.7.2. Drug Stores & Retail Pharmacies
    • 6.7.3. Online Pharmacies
  • 6.8. Market Analysis, Insights and Forecast - By Country
    • 6.8.1. U.S.
    • 6.8.2. Canada

7. Europe Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Temozolomide
    • 7.1.2. Bevacizumab
    • 7.1.3. Carmustine
    • 7.1.4. Lomustine
    • 7.1.5. Procarbazine
    • 7.1.6. Irinotecan
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Alkylating Agents
    • 7.2.2. VEGF/Angiogenesis Inhibitors
    • 7.2.3. Nitrosoureas
    • 7.2.4. Platinum Compounds
    • 7.2.5. Topoisomerase Inhibitors
    • 7.2.6. Immune Checkpoint Inhibitors
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generic
  • 7.5. Market Analysis, Insights and Forecast - By Therapy
    • 7.5.1. Targeted therapy
    • 7.5.2. Immunotherapy
    • 7.5.3. Chemotherapy
    • 7.5.4. Others
  • 7.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.6.1. Oral
    • 7.6.2. Parenteral
  • 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Drug Stores & Retail Pharmacies
    • 7.7.3. Online Pharmacies
  • 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.8.1. U.K.
    • 7.8.2. Germany
    • 7.8.3. France
    • 7.8.4. Italy
    • 7.8.5. Spain
    • 7.8.6. Scandinavia
    • 7.8.7. Rest of Europe

8. Asia Pacific Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Temozolomide
    • 8.1.2. Bevacizumab
    • 8.1.3. Carmustine
    • 8.1.4. Lomustine
    • 8.1.5. Procarbazine
    • 8.1.6. Irinotecan
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Alkylating Agents
    • 8.2.2. VEGF/Angiogenesis Inhibitors
    • 8.2.3. Nitrosoureas
    • 8.2.4. Platinum Compounds
    • 8.2.5. Topoisomerase Inhibitors
    • 8.2.6. Immune Checkpoint Inhibitors
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generic
  • 8.5. Market Analysis, Insights and Forecast - By Therapy
    • 8.5.1. Targeted therapy
    • 8.5.2. Immunotherapy
    • 8.5.3. Chemotherapy
    • 8.5.4. Others
  • 8.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.6.1. Oral
    • 8.6.2. Parenteral
  • 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Drug Stores & Retail Pharmacies
    • 8.7.3. Online Pharmacies
  • 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.8.1. China
    • 8.8.2. Japan
    • 8.8.3. India
    • 8.8.4. Southeast Asia
    • 8.8.5. Australia
    • 8.8.6. Rest of Asia Pacific

9. Latin America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Temozolomide
    • 9.1.2. Bevacizumab
    • 9.1.3. Carmustine
    • 9.1.4. Lomustine
    • 9.1.5. Procarbazine
    • 9.1.6. Irinotecan
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Alkylating Agents
    • 9.2.2. VEGF/Angiogenesis Inhibitors
    • 9.2.3. Nitrosoureas
    • 9.2.4. Platinum Compounds
    • 9.2.5. Topoisomerase Inhibitors
    • 9.2.6. Immune Checkpoint Inhibitors
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generic
  • 9.5. Market Analysis, Insights and Forecast - By Therapy
    • 9.5.1. Targeted therapy
    • 9.5.2. Immunotherapy
    • 9.5.3. Chemotherapy
    • 9.5.4. Others
  • 9.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.6.1. Oral
    • 9.6.2. Parenteral
  • 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Drug Stores & Retail Pharmacies
    • 9.7.3. Online Pharmacies
  • 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.8.1. Brazil
    • 9.8.2. Mexico
    • 9.8.3. Rest of Latin America

10. Middle East & Africa Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Temozolomide
    • 10.1.2. Bevacizumab
    • 10.1.3. Carmustine
    • 10.1.4. Lomustine
    • 10.1.5. Procarbazine
    • 10.1.6. Irinotecan
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Alkylating Agents
    • 10.2.2. VEGF/Angiogenesis Inhibitors
    • 10.2.3. Nitrosoureas
    • 10.2.4. Platinum Compounds
    • 10.2.5. Topoisomerase Inhibitors
    • 10.2.6. Immune Checkpoint Inhibitors
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generic
  • 10.5. Market Analysis, Insights and Forecast - By Therapy
    • 10.5.1. Targeted therapy
    • 10.5.2. Immunotherapy
    • 10.5.3. Chemotherapy
    • 10.5.4. Others
  • 10.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.6.1. Oral
    • 10.6.2. Parenteral
  • 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Drug Stores & Retail Pharmacies
    • 10.7.3. Online Pharmacies
  • 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.8.1. GCC
    • 10.8.2. South Africa
    • 10.8.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co., Inc.
    • 11.2.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.2.3. Teva Pharmaceutical Industries Ltd.
    • 11.2.4. Sun Pharmaceutical Industries Ltd.
    • 11.2.5. Accord Healthcare
    • 11.2.6. Camber Pharmaceuticals, Inc.
    • 11.2.7. Fresenius Kabi AG
    • 11.2.8. Zydus Lifesciences Ltd.
    • 11.2.9. Amneal Pharmaceuticals, Inc.

List of Tables

  • Figure 1: Global Glioblastoma Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Glioblastoma Drugs Market Value Share (%), By Drug, 2025 & 2034
  • Figure 3: Global Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 4: Global Glioblastoma Drugs Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Glioblastoma Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 6: Global Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Glioblastoma Drugs Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 8: Global Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 9: Global Glioblastoma Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 10: North America Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 11: North America Glioblastoma Drugs Market Value Share (%), By Drug, 2025
  • Figure 12: North America Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 13: North America Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 14: North America Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 15: North America Glioblastoma Drugs Market Value Share (%), by Age Group 2025
  • Figure 16: North America Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 17: North America Glioblastoma Drugs Market Value Share (%), by Type, 2025
  • Figure 18: North America Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 19: North America Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 20: North America Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 21: North America Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 22: North America Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 23: North America Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 24: North America Glioblastoma Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 25: North America Glioblastoma Drugs Market Value Share (%), by Country, 2025
  • Figure 26: Europe Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 27: Europe Glioblastoma Drugs Market Value Share (%), By Drug, 2025
  • Figure 28: Europe Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 29: Europe Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 30: Europe Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 31: Europe Glioblastoma Drugs Market Value Share (%), by Age Group 2025
  • Figure 32: Europe Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 33: Europe Glioblastoma Drugs Market Value Share (%), by Type, 2025
  • Figure 34: Europe Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 35: Europe Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 36: Europe Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 37: Europe Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 38: Europe Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 39: Europe Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 40: Europe Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 41: Europe Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 42: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 43: Asia Pacific Glioblastoma Drugs Market Value Share (%), By Drug, 2025
  • Figure 44: Asia Pacific Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 45: Asia Pacific Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 46: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 47: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Age Group 2025
  • Figure 48: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 49: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Type, 2025
  • Figure 50: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 51: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 52: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 53: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 54: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 55: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 56: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 57: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 58: Latin America Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 59: Latin America Glioblastoma Drugs Market Value Share (%), By Drug, 2025
  • Figure 60: Latin America Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 61: Latin America Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 62: Latin America Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 63: Latin America Glioblastoma Drugs Market Value Share (%), by Age Group 2025
  • Figure 64: Latin America Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 65: Latin America Glioblastoma Drugs Market Value Share (%), by Type, 2025
  • Figure 66: Latin America Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 67: Latin America Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 68: Latin America Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 69: Latin America Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 70: Latin America Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 71: Latin America Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 72: Latin America Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 73: Latin America Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 74: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 75: Middle East & Africa Glioblastoma Drugs Market Value Share (%), By Drug, 2025
  • Figure 76: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 77: Middle East & Africa Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 78: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 79: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Age Group 2025
  • Figure 80: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 81: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Type, 2025
  • Figure 82: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 83: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 84: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 85: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 86: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 87: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 88: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 89: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 90: Global Glioblastoma Drugs Market Share (%), by Company, 2025